CN111084806B - 一种治疗或预防冠状病毒感染的药物组合物 - Google Patents
一种治疗或预防冠状病毒感染的药物组合物 Download PDFInfo
- Publication number
- CN111084806B CN111084806B CN202010090724.5A CN202010090724A CN111084806B CN 111084806 B CN111084806 B CN 111084806B CN 202010090724 A CN202010090724 A CN 202010090724A CN 111084806 B CN111084806 B CN 111084806B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- treating
- weight
- coronavirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000001528 Coronaviridae Infections Diseases 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 33
- 241000208843 Arctium Species 0.000 claims abstract description 17
- 235000003130 Arctium lappa Nutrition 0.000 claims abstract description 17
- 235000008078 Arctium minus Nutrition 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 13
- 235000011477 liquorice Nutrition 0.000 claims abstract description 13
- 241000711573 Coronaviridae Species 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 7
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 15
- 241000951473 Schizonepeta Species 0.000 abstract description 9
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 238000001035 drying Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003283 colorimetric indicator Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- -1 nipagin ester Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本申请公开了医药技术领域中的一种用于预防或治疗冠状病毒感染的药物组合物,含有1‑10份牛蒡根、1‑10份荆芥、1‑10份甘草,以上所述的份为重量份。经过药理实验分析,结果表明三者配伍具有很好的抑制冠状病毒的药理活性,并且较单一化合物作用较强,提示三者配伍可以起到协同作用,且其药物组合物的药理活性优于牛蒡子、荆芥穗和甘草的组合物,本申请所提供的药物组合物较为安全,可用于预防或治疗冠状病毒感染制剂,具有一定商业价值。
Description
技术领域
本发明涉及医药技术领域,具体而言,涉及一种治疗或预防冠状病毒感染的药物组合物,其具有抗冠状病毒的药理活性,可用于治疗或预防冠状病毒感染的咽炎、肺炎等呼吸系统疾病。
背景技术
冠状病毒是现代疫情高发的主要病原之一,常常引起人类严重的呼吸系统感染,如导致2003年严重急性呼吸综合征(SARS)和中东呼吸综合征(MERS)等烈性传染病的暴发,特别是2019年末的新型冠状病毒感染肺炎等。对全球公共卫生系统造成极大的冲击,同时,也是人类普通感冒的主要病原之一,儿童感染率较高,主要是呼吸道感染,潜伏期2~14天,各年龄组均有发病,以呼吸道感染为特征,少数可致腹泻、支气管炎、肺炎和胸腔积液等。
人类面临病冠状病毒感染传染病的现实和潜在威胁日益严峻,使得人类应对突发传染病的防控压力日益倍增,但实际情况是:当冠状病毒发生突变或出现新型病毒而导致传染病疫情暴发时,原来的特异性防治药物难以发挥有效的防控效果,而当疫情突然发生时,又使得具有显著疗效的新一代特异性预防和治疗药物难以在短时间内推出,从而导致疫情的迅速扩散,甚至全球范围的灾难性暴发,对社会的政治和经济造成巨大的冲击。因此,筛选光谱抗冠状病毒药物,对于应对冠状病毒感染疫情的传播具有重要意义
发明内容
本发明目的之一在于提供一种治疗或预防冠状病毒感染的药物组合物,降低目前治疗冠状病毒感染临床用药的风险,及易产生抗药性等问题。
解决上述技术问题所采用的技术方案是:一种治疗或预防冠状病毒感染的药物组合物,含有重量份为1~10份的牛蒡根、1~10份的荆芥和1~10份的甘草。
在本发明中,牛蒡根味辛苦,性寒,归肺胃经,具有疏散风热、透疹利咽、解毒消肿之功效。用于风热感冒,冠状病毒感染,麻疹不透,痈肿疮毒,痄腮喉痹。荆芥味辛,性微温。归肺、肝经。具有祛风解表,透疹消疮,止血之功效。用于外感表证,感冒发热,头痛,咳嗽,冠状病毒感染,麻疹不透,风疹瘙痒,疮疡初起有表证,吐衄下血。甘草味甘,性平。归心、肺、脾、胃经。具有益气补中、清热解毒、祛痰止咳、缓急止痛与调和药性之功。本发明精选传统利中药材,通过对牛蒡根、荆芥、甘草三种有效成分的组方配伍研究,对其有效成分的深入研究,科学配伍组方,将传统中医理论与现代科学相结合,研制出疗效好、副作用少,服用方便、价格经济的预防或治疗冠状病毒感染药物组合物,从而满足社会需求,并带来较好的经济效益和社会效益,经过药理实验分析,结果表明三者配伍具有很好的抑制冠状病毒的药理活性,并且较单一化合物作用较强,提示三者配伍可以起到协同作用,且其药物组合物的药理活性优于牛蒡子、荆芥穗和甘草的组合物。
上述药物组合物具有良好的抑制冠状病毒的药理活性,并且非常适合工业化生产。
优选的,所述药物组合物含有重量份为6份的牛蒡根、1份的荆芥和2份的甘草。
本发明目的之二在于提供一种预防或治疗冠状病毒感染的药物,含有以上所述的药物组合物以及药学上可接受的赋形剂,这些赋形剂(其中,赋形剂的重量份数不超过60份)包括但不限于:淀粉、乳糖、甘露醇、山梨醇、微晶纤维素、交联聚维酮、交联羧甲基纤维素钠、硬脂酸镁、滑石粉、微粉硅胶等。
优选剂型为固体口服制剂、液体口服制剂及外用膏剂。
本发明的药物组合物采用常规方法混合制备,药物组合物制剂采用制剂领域常规的制备方法制备。
治疗或预防冠状病毒感染药物胶囊剂制备:在上述治疗或预防冠状病毒感染药物组合物中加入淀粉、微晶纤维素、乳糖等辅料的一种或几种,混匀,制粒,烘干,过筛,装胶囊,每粒胶囊重0.2~0.5g,即成治疗或预防冠状病毒感染胶囊。
治疗或预防冠状病毒感染药物片剂制备:在上述治疗或预防冠状病毒感染药物组合物中加入淀粉、微晶纤维素、乳糖等辅料的一种或几种,混匀,制粒,烘干,过筛,压片,每片重0.2-0.5g,即成治疗或预防冠状病毒感染片剂。
治疗或预防冠状病毒感染药物糖浆剂制备:在上述治疗或预防冠状病毒感染药物组合物中加水提取,加入单糖浆、尼泊金酯、苯甲酸,混匀后灌装至有色玻璃瓶中,即成镇咳祛痰糖浆剂。
本发明所提供的药物组合物药效成分明确,治疗作用强,非常适合工业化生产,将会产生很好的社会效益和经济效益。
进一步的,所述冠状病毒为MERS病毒、MHV病毒、SARS病毒或者2019新型冠状病毒。
具体实施方式
为更好地理解本发明的本质,下面通过对本发明较佳实施方式的进行描述,详细说明本发明但不限制本发明。
实施例1:组合物1制备
按重量份数取牛蒡根药材6份、荆芥药材1份、甘草药材2份粉碎,加12倍量水提取两次,过滤,合并提取液,减压浓缩至1倍药材量体积,加5倍量70%乙醇,静置过夜,取上清液,减压回收乙醇,干燥,即得。
实施例2:组合物2制备
按重量份数取牛蒡根药材10份、荆芥药材1份、甘草药材1份粉碎,加12倍量水提取两次,过滤,合并提取液,减压浓缩至1倍药材量体积,加5倍量70%乙醇,静置过夜,取上清液,减压回收乙醇,干燥,即得。
实施例3:组合物3制备
按重量份数取牛蒡根药材1份、荆芥药材1份、甘草药材10份粉碎,加12倍量水提取两次,过滤,合并提取液,减压浓缩至1倍药材量体积,加5倍量70%乙醇,静置过夜,取上清液,减压回收乙醇,干燥,即得。
实施例4:组合物4制备
按重量份数取牛蒡子药材6份、荆芥穗药材1份、甘草药材2份粉碎,加12倍量水提取两次,过滤,合并提取液,减压浓缩至1倍药材量体积,加5倍量70%乙醇,静置过夜,取上清液,减压回收乙醇,干燥,即得。
实验验证:药物组合物体外抗病毒作用
1.材料
1.1冠状病毒毒株:MERS-CoV,MHV-A59。
1.2细胞模型:猴肾细胞系Vero。
培养条件:DMEM+10%胎牛血清,37℃,5%CO2。
1.3检测样品:样品编号和浓度见表1。
2.原理和方法
2.1药物的细胞毒性检测
采用了alamarBlue(Invitrogen公司)试剂盒检测药物对细胞的毒性作用。
实验原理:alamarBlue是一种氧化还原指示剂,能根据代谢活性产生吸光度变化和荧光信号。alamarBlue易溶于水,其氧化形式进入细胞后经线粒体酶还原产生可测量的荧光及颜色变化,用于细胞活性和细胞增殖的定量分析以及体外细胞毒性研究。这种测定是基于具有代谢活性的细胞将试剂转换成荧光和比色指示剂的能力,受损和无活性细胞具有较低的天然代谢活性,对应的信号较低。因此荧光信号强弱,可以反映细胞活性的高低。
方法步骤:Vero细胞接种于96孔细胞培养板中,细胞贴壁后备用。用DMSO将药物从200倍起始浓度3倍梯度连续稀释成6个梯度,然后用细胞维持液(DMEM+4%血清)稀释成含药物的培养液,每浓度梯度单孔检测。加药培养72h后,弃去培养上清,加入含有alamarBlue的培养基,37℃孵育2h,荧光检测alamarBlue的还原情况,激发光570nm,发射光595nm。
细胞活性(%)=(样品孔-空白对照)/(细胞对照-空白对照)×100%
2.2药物对MERS-CoV,MHV-A59病毒的抑制试验
MERS-CoV,MHV-A59感染Vero细胞后,感染细胞会发生固缩、互相融合、形成葡萄串状或星状等病变,通过观察CPE和检测细胞存活率可以判断药物对病毒复制的抑制情况。
方法步骤:Vero细胞接种于96孔细胞培养板中,待细胞长成单层后加入100ul含2x药物的维持培养基和100ul DMEM稀释的病毒液,37℃培养。每天观察并记录细胞出现特异性CPE情况,培养72h后(病毒对照孔100%病变)检测细胞存活率。
实验设细胞对照组(无病毒感染),病毒对照组(病毒感染后未加药物孔),阳性药物(利巴韦林)对照孔。
抑制率(%)=(药物组-病毒对照组)/(细胞对照组-病毒对照组)×100%
3.结果
3.1药物样品对细胞的毒性检测及对MERS-CoV,MHV-A59抑制活性检测
药物样品稀释所用溶剂,最高溶解浓度,最高测试浓度,CC50,EC50以及SI(选择指数)如表1所示。
表1:各药物样品实验结果
“-”,未检测到明显细胞毒性或抑制冠状病毒活性,其CC50值大于最大测试浓度。
4.结论
各药物组合物均表现出较好的抗MERS-CoV,MHV-A59病毒活性作用,药物组合物的抗冠状病毒效果优于单味药材,并且在组合物中采用牛蒡根及荆芥的效果优于牛蒡子和荆芥穗。在100ug/ml浓度下完全观察不到特异性CPE,细胞形态与细胞对照组相似,33ug/mlCPE程度为+++。以上实验证明各药物组合物具有在制备抗冠状病毒药物的应用前景。
应用1:胶囊剂制备
将重量份比例的6份牛蒡根、1份荆芥、2份甘草,加12倍量水提取两次,减压浓缩至1倍药材量,加入5倍量70%乙醇,静置过夜,去上清液,减压干燥后,加入淀粉、微晶纤维素、乳糖等辅料的一种或几种,混匀,制粒,烘干,过筛,装胶囊,每粒胶囊重0.2-0.5g,即成本发明的胶囊。
应用2:片剂制备
将重量份比例的6份牛蒡根、1份荆芥、2份甘草,加12倍量水提取两次,减压浓缩至1倍药材量,加入5倍量70%乙醇,静置过夜,去上清液,减压干燥后,加入淀粉、微晶纤维素、乳糖等辅料的一种或几种,混匀,制粒,烘干,过筛,压片,即成本发明的片剂。
应用3:糖浆剂制备
将重量份比例的6份牛蒡根、1份荆芥、2份甘草,加12倍量水提取两次,减压浓缩至适量,加入单糖浆、尼泊金酯、苯甲酸,混匀后灌装至有色玻璃瓶中,即成本发明的糖浆剂。
Claims (4)
1.一种药物组合物,其特征在于:由重量份为1~10份的牛蒡根、1~10份的荆芥和1~10份的甘草组成。
2.根据权利要求1所述的药物组合物,其特征在于:由重量份为6份的牛蒡根、1份的荆芥和2份的甘草组成。
3.根据权利要求1或2所述的药物组合物在制备预防或治疗冠状病毒感染制剂中的用途,其特征在于:所述冠状病毒为MERS-CoV病毒或者MHV-A59病毒。
4.一种预防或治疗冠状病毒感染的药物组合物,含有如权利要求1或2所述的药物组合物以及药学上可接受的辅料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010090724.5A CN111084806B (zh) | 2020-02-13 | 2020-02-13 | 一种治疗或预防冠状病毒感染的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010090724.5A CN111084806B (zh) | 2020-02-13 | 2020-02-13 | 一种治疗或预防冠状病毒感染的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111084806A CN111084806A (zh) | 2020-05-01 |
CN111084806B true CN111084806B (zh) | 2021-09-07 |
Family
ID=70399917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010090724.5A Active CN111084806B (zh) | 2020-02-13 | 2020-02-13 | 一种治疗或预防冠状病毒感染的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111084806B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2527989A1 (en) * | 2003-06-06 | 2004-12-16 | Johann Wolfgang Goethe University | Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome (sars) |
CN105434925A (zh) * | 2015-12-10 | 2016-03-30 | 覃瑞权 | 治疗慢性咽炎的中药组合物 |
CN107085065A (zh) * | 2017-06-27 | 2017-08-22 | 深圳海王医药科技研究院有限公司 | 一种同时测定牛蒡苷、甘草酸和胡薄荷酮含量的方法 |
-
2020
- 2020-02-13 CN CN202010090724.5A patent/CN111084806B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2527989A1 (en) * | 2003-06-06 | 2004-12-16 | Johann Wolfgang Goethe University | Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome (sars) |
CN105434925A (zh) * | 2015-12-10 | 2016-03-30 | 覃瑞权 | 治疗慢性咽炎的中药组合物 |
CN107085065A (zh) * | 2017-06-27 | 2017-08-22 | 深圳海王医药科技研究院有限公司 | 一种同时测定牛蒡苷、甘草酸和胡薄荷酮含量的方法 |
Non-Patent Citations (2)
Title |
---|
核酸靶分子与某些中药成分的非共价作用研究;宋凤瑞 等;《分析化学研究简报》;20051231;第33卷(第12期);第1743-1746页 * |
甘草细胞悬浮培养系的建立与悬浮细胞中活性成分分析;包金龙;《中国优秀硕士学位论文全文数据库 农业科技辑》;20120215(第2期);第4页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111084806A (zh) | 2020-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113209164B (zh) | 黄芩、连翘、金银花主要成分及其组合物在抗冠状病毒中的应用 | |
CN113244211B (zh) | 黄芩素、黄芩苷用于制备冠状病毒SARS-CoV-2的3CL蛋白酶的抑制剂的用途 | |
Chen et al. | A laboratory evaluation of medicinal herbs used in china for the treatment of hand, foot, and mouth disease | |
CN117427085A (zh) | 金诺芬等老药及其组合物在抗单正链rna病毒中的应用 | |
CN111150755B (zh) | 具有防治病毒性疾病的中药组合物及其应用 | |
CN101129455B (zh) | 苦豆子提取物及其生产方法和应用 | |
CN101669979B (zh) | 滨蒿提取物及其生产方法和应用 | |
WO2022022020A1 (zh) | 一种中药组合物、制备方法及应用 | |
CN113332363A (zh) | 茶叶提取物及其组合物在抗冠状病毒中的应用 | |
CN108524685B (zh) | 一种治疗儿童疱疹性咽峡炎的组合物及其应用 | |
CN111084806B (zh) | 一种治疗或预防冠状病毒感染的药物组合物 | |
CN108403858B (zh) | 一种治疗手足口病的裸花紫珠提取物组合物及其应用 | |
CN111671846A (zh) | 金贝制剂在抗冠状病毒中的应用 | |
CN111632116A (zh) | 一种抗病毒性感冒中药制剂的制备方法 | |
CN107753823B (zh) | 一种治疗或预防手足口病的中药组合物 | |
CN106344549B (zh) | 大黄酸在制备预防和/或治疗手足口病药物中的应用 | |
CN111228368B (zh) | 中药组合物在制备用于防治新型冠状病毒合并肝损伤药物中的应用 | |
CN113855688A (zh) | Vina-ginsenoside R18在制备抗登革病毒药物制剂中的应用 | |
CN114306354A (zh) | 一种具有抗2型登革病毒作用的植物单体及其应用 | |
US20080102140A1 (en) | Use of solidago virgaurea in the treatment and prevention of viral infections | |
CN116531471B (zh) | 一种用于治疗病毒感染湿热袭肺证的中药合剂 | |
CN113975267B (zh) | 6α-hydroxyeurycomalactone在制备抗登革病毒药物的应用 | |
CN113230253B (zh) | 抗病毒组合物及其在制备预防和/或治疗疱疹病毒药物中的应用 | |
CN113975268B (zh) | 5,6-dehydroeurycomalactone在制备抗登革病毒药物的应用 | |
CN106138259B (zh) | 一种治疗风热感冒的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231016 Address after: No. 455 Shibei Road, Yunyan District, Guiyang City, Guizhou Province, 550001 Patentee after: GUIZHOU HUANGGUOSHU LISHUANG PHARMACEUTICAL Co.,Ltd. Address before: 563000 No. 201, Dalian Road, Huichuan District, Zunyi City, Guizhou Province Patentee before: ZUNYI MEDICAL University |
|
TR01 | Transfer of patent right |